Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.42 |
| ▸ | CA1 | P00915 | 7/20 | 0.40 |
| ▸ | CA2 | P00918 | 7/20 | 0.40 |
| ▸ | CA9 | Q16790 | 7/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6306624 | 0.92 | CA9 (0.47) | PTGS2CA1CA2CA9PTGS1 | |
| SCHEMBL6746808 | 0.88 | MARS1 (0.38) | PTGS2CA1CA2CA9PTGS1 | |
| SCHEMBL6307500 | 0.87 | CA1 (0.49) | PTGS2CA1CA2CA9CHRNA7 | |
| SCHEMBL6308681 | 0.85 | PTGS2 (0.43) | PTGS2CA1CA2CA9PTGS1 | |
| SCHEMBL6308438 | 0.82 | PTGS2 (0.43) | PTGS2CA1CA2CA9PTGS1 | |
| SCHEMBL6308577 | 0.82 | PTGS2 (0.61) | PTGS2CA1CA2CA9CHRNA7 | |
| SCHEMBL6309342 | 0.82 | PTGS2 (0.48) | PTGS2CA1CA2CA9CHRNA7 | |
| SCHEMBL8639929 | 0.81 | CA1 (0.49) | PTGS2CA1CA2CA9CHRNA7 | |
| SCHEMBL6307486 | 0.80 | PTGS2 (0.43) | PTGS2CA1CA2CA9CHRNA7 | |
| SCHEMBL8317362 | 0.80 | PTGS2 (0.49) | PTGS2CHRNA7PTGS1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6696477-B2 | AS ANTIINFLAMMATORY AGENTS | PHARMACIA CORPORATION | 2004-02-24 | — | — | US | claimed |
| US-20020058810-A1 | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | PHARMACIA CORPORATION | 2002-05-16 | — | — | US | claimed |
| US-6875785-B2 | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | PHARMACIA CORPORATION (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040248943-A9 | Pyrazole substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | PHARMACIA CORPORATION | 2004-12-09 | — | — | US | disclosed |
| US-6753344-B2 | SULFONYL OR SULFONAMIDE SUBSTITUTED BENZENE DERIVATIVE CONTAINING HYDROXYUREA GROUP; USEFUL AS ANTIINFLAMMATORY AGENT | PHARMACIA CORPORATION | 2004-06-22 | — | — | US | disclosed |
| US-6696477-B2 | AS ANTIINFLAMMATORY AGENTS | PHARMACIA CORPORATION | 2004-02-24 | — | — | US | disclosed |
| US-20030176708-A1 | Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | PHARMACIA CORPORATION | 2003-09-18 | — | — | US | disclosed |
| US-20030119886-A1 | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | PHARMACIA CORPORATION | 2003-06-26 | — | — | US | disclosed |
| US-20030073722-A1 | Pyrazole substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | PHARMACIA CORPORATION | 2003-04-17 | — | — | US | disclosed |
| US-6515014-B2 | Aminosulfonyl- or alkylsulfonylphenyl-heterocyclylalkylhydroxyamic acid or hydroxyurea derivatives; treating asthma and arthritis | G. D. SEARLE & CO. | 2003-02-04 | — | — | US | disclosed |
| US-6512121-B2 | Non-steroidal antiinflammatory agent; enzyme sub-type specific; inhibits prostaglandin and/or leukotriene production | G.D. SEARLE & CO. | 2003-01-28 | — | — | US | disclosed |
| US-6432999-B2 | ANTIINFLAMMATORY AGENTS; ANTIASTHMATIC AGENTS; ANTIPYRETICS; ANALGESICS; ANTIARTHRITIC AGENTS; ANTIISCHEMIC AGENTS | PHARMACIA CORPORATION | 2002-08-13 | — | — | US | disclosed |
| US-20020058810-A1 | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | PHARMACIA CORPORATION | 2002-05-16 | — | — | US | disclosed |
| US-20020055525-A1 | Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | TALLEY JOHN J (US) | 2002-05-09 | — | — | US | disclosed |
| US-20020028945-A1 | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | TALLEY JOHN J (US) | 2002-03-07 | — | — | US | disclosed |
| US-20010056189-A1 | Pyrazole substituted hydroxamic acid derivatives as cyclooxxgenase-2 and 5- lipoxygenase inhibitors | TALLEY JOHN J (US) | 2001-12-27 | — | — | US | disclosed |
| EP-0828718-A1 | HETEROCYCLO SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996038418-A1 | HETEROCYCLO SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028945-A1 | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, ALOX12, ALOX15 | PTGS2 7/4885CA1 1781/4885CA2 940/4885 |
| US-20030119886-A1 | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, ALOX12, ALOX15 | PTGS2 7/4885CA1 1781/4885CA2 940/4885 |
| US-20020058810-A1 | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, ALOX12, ALOX15 | PTGS2 7/4885CA1 1781/4885CA2 940/4885 |
| US-20040248943-A9 | Pyrazole substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, ALOX15, ALOX12 | PTGS2 5/4885CA1 2343/4885CA2 1331/4885 |
| US-20030073722-A1 | Pyrazole substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, ALOX15, ALOX12 | PTGS2 5/4885CA1 2343/4885CA2 1331/4885 |
| US-20010056189-A1 | Pyrazole substituted hydroxamic acid derivatives as cyclooxxgenase-2 and 5- lipoxygenase inhibitors | ALOX5, ALOX15, ALOX12 | PTGS2 6/4885CA1 1759/4885CA2 1109/4885 |
| US-20030176708-A1 | Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, ALOX15, ALOX12 | PTGS2 5/4885CA1 1995/4885CA2 857/4885 |
| US-20020055525-A1 | Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, ALOX15, ALOX12 | PTGS2 5/4885CA1 1995/4885CA2 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.